Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• N-methyl-D-aspartate (NMDA) receptor antagonists like ketamine demonstrate rapid antidepressant effects in treatment-resistant depression (TRD).
• Nitrous oxide, an inhalational anesthetic and NMDA receptor antagonist, was investigated for its potential rapid antidepressant properties in TRD.

Purpose of the Study:

• To evaluate the efficacy of nitrous oxide as a rapid-acting antidepressant treatment for patients with TRD.
• To assess the safety and tolerability of nitrous oxide in this patient population.

Main Methods:

• A blinded, placebo-controlled crossover trial involving 20 patients diagnosed with TRD.
• Participants received either 50% nitrous oxide/50% oxygen or a placebo (50% nitrogen/50% oxygen) for 1 hour.
• The primary outcome measure was the change in the 21-item Hamilton Depression Rating Scale (HDRS-21) at 24 hours post-treatment.

Main Results:

• Nitrous oxide significantly improved depressive symptoms at both 2 and 24 hours compared to placebo (p < .001).
• Twenty percent of patients achieved treatment response (≥50% HDRS-21 reduction) and 15% achieved remission (HDRS-21 ≤ 7 points) with nitrous oxide.
• Adverse events were mild, moderate, and transient, with no serious adverse events reported.

Conclusions:

• This proof-of-concept trial indicates that nitrous oxide possesses rapid and significant antidepressant effects in patients suffering from TRD.
• Nitrous oxide represents a potential novel therapeutic option for the acute management of treatment-resistant depression.